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Abstract 
Background: Deceased organ donors represent an untapped source of therapeutic bone marrow (BM) that can be 
recovered in 3–5 times the volume of that obtained from living donors, tested for quality, cryopreserved, and banked 
indefinitely for future on-demand use. A challenge for a future BM banking system will be to manage the prolonged 
ischemia times that are inevitable when bones procured at geographically-dispersed locations are shipped to distant 
facilities for processing. Our objectives were to: (a) quantify, under realistic field conditions, the relationship between 
ischemia time and the quality of hematopoietic stem and progenitor cells (HSPCs) derived from deceased-donor BM; 
(b) identify ischemia-time boundaries beyond which HSPC quality is adversely affected; (c) investigate whole-body 
cooling as a strategy for preserving cell quality; and (d) investigate processing experience as a variable affecting 
quality.
Methods: Seventy-five bones from 62 donors were analyzed for CD34+ viability following their exposure to vari-
ous periods of warm-ischemia time (WIT), cold-ischemia time (CIT), and body-cooling time (BCT). Regression models 
were developed to quantify the independent associations of WIT, CIT, and BCT, with the viability and function of 
recovered HSPCs.
Results: Results demonstrate that under “real-world” scenarios: (a) combinations of warm- and cold-ischemia times 
favorable to the recovery of high-quality HSPCs are achievable (e.g., CD34+ cell viabilities in the range of 80–90% 
were commonly observed); (b) body cooling prior to bone recovery is detrimental to cell viability (e.g., CD34+ viability 
< 73% with, vs. > 89% without body cooling); (c) vertebral bodies (VBs) are a superior source of HSPCs compared to ilia 
(IL) (e.g., %CD34+ viability > 80% when VBs were the source, vs. < 74% when IL were the source); and (d) processing 
experience is a critical variable affecting quality.
Conclusions: Our models can be used by an emerging BM banking system to formulate ischemia-time tolerance 
limits and data-driven HSPC quality-acceptance standards.
Keywords: Deceased-donor bone marrow, Bone marrow banking, Bone marrow ischemia time, Hematopoietic stem 
cell transplant
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Background
Deceased-donor bone marrow (BM) represents a large, 
untapped source of hematopoietic stem and progenitor 
cells (HSPCs) that could be cryopreserved and banked 
for future on-demand use in bone marrow transplant 
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part from the recognition that HSPCs could be immedi-
ately available during surges in demand, as, for example, 
following a mass casualty event such as a nuclear disaster 
resulting in widespread bone-marrow failure [1, 2]. Inter-
est has been further solidified by recent advances in the 
induction of immune tolerance via the infusion of donor 
BM cells to establish durable or transient mixed chimer-
ism and/or peripheral immunomodulation in recipients 
of solid organ and vascular composite allograft (VCA) 
transplants [3–5]. A donor BM bank would provide a 
repository for future tolerance induction and immu-
nomodulation procedures that use delayed protocols. 
Such procedures have already been proven successful in 
non-human primates [6, 7].
Cryopreservation and banking of BM from deceased 
organ donors will require the establishment of BM banks, 
similar in concept to umbilical cord blood banks. As 
with cord blood, it is well-established that BM remains 
biologically functional following cryopreservation and 
can serve as a genetically diverse, on-demand source of 
stem cell grafts [8–11]. The national Organ Procurement 
Organization (OPO) network, which has been active 
in the United States (US) for over 50 years, provides an 
existing, well-functioning infrastructure for procuring 
and transporting bone tissue recovered from deceased 
donors. However, organizing an integrated organ-donor 
BM procurement and banking system that capitalizes 
on this infrastructure, will require coordinated efforts, 
involving the recovery and safe shipment of biological 
material to specialized BM cell-processing centers appro-
priately scaled for clinical production.
A critical issue, which typically has not been viewed as 
significant in the case of living BM donors, is the man-
agement of the prolonged ischemia times that are inevi-
table during recovery and shipment of bones recovered 
from deceased donors. Before a clinical production sys-
tem can be brought to scale, it will be necessary to deter-
mine how variations in warm- and cold-ischemia times 
influence the quality of HSPCs derived from bones recov-
ered at geographically dispersed locations, and shipped 
long distances to centralized processing facilities. And it 
will be necessary to establish upper tolerance limits for 
both warm- and cold-ischemia, which, if exceeded, would 
likely render the quality and functionality of HSPCs 
unacceptable for therapeutic use.
Additionally, the impact of whole-body cooling in the 
context of deceased-donor bone recovery needs to be 
better understood. Current tissue-banking guidelines 
in the US allow tissues to be recovered from deceased 
donors up to 24 h following asystole, provided the body 
is refrigerated within 12 h of cardiac arrest [12]. However, 
body cooling is a variable that has not been investigated 
systematically in relation to the recovery of BM, and it is 
one that may require different criteria than those estab-
lished for tissue recovery.
Here we present our results for the first time, which 
quantify the associations of ischemia time and whole-
body cooling, with the quality of HSPCs recovered from 
the vertebral bodies and ilia of deceased organ donors. 
Our analyses show that high-quality, functional HSPCs 
can be obtained from deceased donors even after recov-
ered bones are subjected to cumulative warm- and 
cold-ischemia times exceeding 40 h, provided that body 
cooling, which is shown to be detrimental to viability, is 
avoided. These findings should be useful in establishing 
industry standards for warm- and cold-ischemia-time 
tolerance limits and HSPC quality acceptance criteria for 
BM derived from deceased organ donors.
Materials and methods
Study design
This is a pragmatic [13] observational field study 
designed to model the effects of ischemia and body-cool-
ing times on the viability and function of HSPCs recov-
ered from the BM of deceased organ donors. To assure 
the study’s external validity (generalizability) we secured 
the participation of multiple OPOs operating under nor-
mal field conditions. Except for special training related 
to the details of bone recovery and shipment (see below), 
usual procurement conditions were in effect. Because the 
OPOs were geographically dispersed, the collected data 
cover the full spectrum of ischemia times likely to be 
seen under “real-world” procurement and shipping sce-
narios. Recovered bones were shipped to one of two pro-
cessing facilities located in Centennial, CO (Facility A) or 
Indianapolis, IN (Facility B).
Donor tissue procurement and transport
Previously developed clinical recovery methods com-
bined with subsequent experience in the ongoing 
VCA transplant immunomodulation clinical trial at 
Johns Hopkins University (ClinicalTrials.gov Identifier: 
NCT01459107) formed the basis for the procurement 
and transport protocols [4, 14–16]. However, these pro-
tocols required optimization and validation to ensure 
that multiple OPOs could reliably operationalize them in 
a manner that allowed for the production of consistent 
yields of functionally viable HSPCs after cross-country 
transport of recovered bones. To that end, a streamlined 
OPO recovery procedure, combined with dedicated kits 
and centralized training on recovery and shipment were 
employed.
Vertebral sections from T-8 through L-5 (Facility A 
and B) and/or ilia (Facility A, only) were procured by six 
OPOs: Gift of Hope (Itasca, IL); Donor Alliance (Den-
ver, CO); Iowa Donor Network (North Liberty, IA); Mid 
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America Transplant (St. Louis, MO); and Nevada Donor 
Network (Las Vegas, NV). Bones were recovered by OPO 
personnel using an osteotome and mallet under an IRB 
approved protocol from research-consented organ and 
tissue donors. Unprocessed bones were wrapped in lap 
sponges and towels soaked in saline and placed in triple-
sealed bags to ensure moisture retention during ship-
ment. Wrapped specimens were shipped overnight on 
wet ice.
Manual debriding
Upon receipt, in an ISO 5 clean room (Facility A) or a 
Biological Safety Cabinet (Facility B), soft tissue was 
manually debrided using scalpels and gouges. Once vis-
ible, the pedicles were removed using either a tissue 
processing band saw or a Stryker System 6 Saw (Stryker, 
Kalamazoo, MI) leaving only the connected vertebral 
bodies. Using a boning knife (Facility B) or tissue pro-
cessing band saw (Facility A), vertebral bodies were sepa-
rated at the intervertebral disc. Remaining intervertebral 
disc and soft tissue were removed with a scalpel, leaving 
clean, separated VBs. Ilium soft tissue was removed with 
gouges and a scalpel. Care was taken to ensure that the 
cortical bone was not breached to preserve and protect 
the hypoxic cancellous BM throughout the entire debrid-
ing process (Fig. 1).
Using a saw and/or anvil shears, VBs and IL were cut 
into 5  cm3 pieces small enough for fragmenting with a 
bone grinder. The pieces were immediately submerged 
into 500 mL processing medium (Iscove’s Modified Dul-
becco’s Medium containing 100 U/mL DNase, 10 U/mL 
heparin, and 2.5% human serum albumin). IMDM is suit-
able for rapidly proliferating high-density cell cultures 
and ideal for supporting T- and B-lymphocytes. DNase 
is essential for the mitigation of cell clumping as a result 
of DNA release from dying cells and post-mortem stress 
on deceased-donor derived BM. Heparin was used as an 
anticoagulant. HSA provided a protein source to prevent 
cell adherence and adsorption to surfaces (Fig. 1).
Grinding and elution
An electric bone grinder was assembled in an ISO-5 
cleanroom (Facility A), and a purpose-built bone grinder 







Fig. 1 Source material and processing steps for production of deceased-donor derived bone marrow. a.1 a block of vertebral bodies prior to 
debriding and disarticulation; a.2 cleaned and disarticulated vertebral bodies ready for processing; b.1 a hemipelvis ready for debriding; b.2 Ilium 
debrided and ready for processing; c cut and ground bone ready for marrow extraction (bones were processed independently); d processed bone 
marrow in final packaging
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a Biological Safety Cabinet (Facility B). In both facilities, 
a 2  L stainless steel beaker containing 100  mL of fresh 
processing medium was placed under the grinding head 
to catch bone fragments and media flow-through. Bone 
types were kept separate if both VB and IL from the same 
donor were processed. Processing medium was used to 
rinse the grinder throughout the process to prevent bone 
from drying and sticking to the chamber. Once all bone 
pieces were ground, the chamber was thoroughly rinsed 
with fresh processing media. The final volume in the 
stainless-steel beaker was typically around 750 mL.
Stainless steel sieves were stacked with a No. 40 
(425  µm) on top of a No. 80 (177  µm) and seated over 
a round catch-pan (WS Tyler, St. Catherines, ON). The 
stainless-steel beaker was swirled and poured over the 
sieves. Bone fragments were distributed evenly on top 
of the sieve and rinsed with 250  mL of fresh process-
ing medium. The sieved BM product, approximately 
1000 mL, was transferred to a sterile pack for final analy-
sis. The HSPC extraction process took 6–8  h following 
receipt by the processing facility, depending on the qual-
ity of the recovery and the number of VBs received.
Nucleated cell counts
An aliquot of BM extract was subjected to red blood 
cell lysis with ammonium chloride RBC lysis buffer. In 
a 15  mL conical tube, 4  mL of 9% ammonium chloride 
was added to 1 mL of BM cell suspension and incubated 
for 5 min at room temperature. Following incubation, the 
lysed sample was filled to the top of the tube with IMDM 
containing 100 U/mL DNase, 10 U/mL heparin, and 2.5% 
HSA processing medium. The lysed sample was centri-
fuged at 300×g for 5 min and decanted. The sample was 
then washed with 15 mL of processing medium, centri-
fuged at 300 x g for 5 min, and decanted. Finally, the lysed 
cells were re-suspended with 1 mL of the same process-
ing medium. Viable nucleated cell counts were obtained 
using Trypan blue and a hemocytometer.
Flow cytometry
Flow Cytometry was performed using an ACEA Bio-
sciences NovoCyte 2060R equipped with 488  nm and 
640 nm lasers. ISHAGE methods were used to enumer-
ate CD45+ and CD34+ cells [16]. 500 µL of lysed bone 
marrow extract was stained for 15  min with 2  µL each 
of CD45-FITC, CD34-APC, 7-AAD, and Annexin-PE. 
All conjugated antibodies were purchased from BD 
Biosciences and 7-AAD was obtained from Tonbo Bio-
sciences. Cells were also stained with individual con-
jugate antibodies for controls and compensation. After 
incubating for 15 min, cells were washed with Dulbecco’s 
phosphate buffered saline, centrifuged, and re-suspended 
in 500 µL of PBS. These samples were run directly on the 
flow cytometer and analyzed using the ISHAGE gating 
scheme [16]. For each sample, 100,000 total events gated 
on the Singlets gate were collected.
Colony forming unit (CFU) assay
The concentration of RBC lysed cell suspension was first 
adjusted to 105 viable cells/mL with processing medium 
before adding 250  µL to 2.5  mL of semisolid medium, 
Methocult Optimum (Stem Cell Technologies, Vancou-
ver, Canada) and then vigorously vortexed to achieve 
adequate mixing. A 3  cc syringe was used to remove at 
least 2.2  mL of Methocult containing cells. 1.1  mL was 
dispensed into each of two 35  mm non-tissue culture 
treated dishes. The dishes were covered and tilted to 
ensure coating of the entire plate surface with Methoc-
ult. The two dishes were placed inside a larger 100 mm 
petri dish with a third uncovered 35 mm dish containing 
sterile deionized water to humidify the plate. Plates were 
incubated for 14  days at 37  °C, 5%  CO2 before scoring 
colonies.
Numbers of donors and bone marrow samples utilized 
for statistical modeling
Seventy-five bones from 62 donors were initially received 
by the two BM processing facilities. The numbers of 
samples with complete data records differed depend-
ing on the outcome being modeled. Table  1 provides a 
breakdown of the numbers received and the numbers 
with complete data available for statistical modeling by 
outcome.
Definition of ischemia time
Total ischemia was defined as the time interval from 
death (when the donor’s arterial system was cross-
clamped and circulation ceased) to start of BM recov-
ery at the processing facility. For purposes of statistical 
modeling, this total interval was separated into three 
successive and mutually exclusive time components: 
(a) Warm-Ischemia Time (WIT): Beginning at time of 
death and ending either when bones were recovered and 
packed on ice, or when the body was placed in a cooler. 
(b) Body-Cooling Time (BCT): Beginning when the body 
was placed in the cooler and ending when recovered 
bones were packed on ice. (c) Cold-Ischemia Time (CIT): 
Table 1 Numbers of donors and bones with complete data 
records available for analysis
Modeled Outcome Donors Bones VB IL
%CD34+ 62 75 52 23
CFU-TOTAL/105 54 67 42 25
CFU-GM  105 54 66 41 25
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Beginning when recovered bones were packed on ice and 
ending when processing began for extraction of HSPCs. 
Thus, Total Ischemia Time = (WIT) + (BCT) + (CIT). 
When body cooling was not used, BCT was coded zero 
and Total Ischemia Time = (WIT) + (CIT). Ischemia 
times were considered the main variables of interest in 
statistical models.
Definition of experience
Because this was the first series in our hands in which 
BM was processed from the bones of deceased donors, 
we hypothesized that HSPC quality might improve with 
learning as we gained more processing experience. This 
hypothesis rests on long-established research demon-
strating that learning exerts significant effects on out-
comes and costs in both industrial manufacturing [17] 
and medical practice settings [18–20]. To control for 
learning, we created a variable, EXPERIENCE, defined as 
the number of donors processed prior to the current one. 
For the ith donor, EXPERIENCE was coded i − 1, to indi-
cate that EXPERIENCE is always one less than the serial 
number of the current case being processed. Because 
Facility A began processing BM 5 months before Facility 
B, and because Facility B had the advantage of participat-
ing in and learning from cases processed at Facility A, we 
hypothesized that the two facilities would have different 
learning trajectories. To account for this possible dif-
ference, each facility’s experience was coded separately. 
To identify the facilities in the model, we coded Facil-
ity A = 1 and Facility B = 0. The effect of EXPERIENCE 
was initially estimated in separate regression models and 
subsequently incorporated as a covariate in final adjusted 
models to control for the effect of learning on outcomes 
(see Additional file: Appendix S1 for details).
Other covariates
Other variables tested in statistical models were: (1) 
BONE TYPE, vertebral bodies (VB) and ilia (IL), (rep-
resenting the two sources of BM cells, coded VB = 1; 
IL = 0); DONOR SEX (percent male); and DONER AGE 
(years). These additional covariates were treated as exog-
enous factors and were included in final models only if 
they were statistically significant, or they improved the 
model’s performance.
Outcome variables
Outcomes were defined according to three hallmarks of 
potential in vivo utility: (a) The proportion of recovered 
CD34+ cells that were viable (%CD34+) determined by 
7-AAD, (b) The total number of colony forming units 
(CFUs) per  105 total nucleated cells (TNC) plated (CFU-
TOTAL), and (c) The number of CFU granulocyte-mac-
rophages detected per  105 nucleated cells (CFU-GM).
Summary statistics
Donor and processing-facility characteristics, ischemia 
times, and outcome measures were summarized as 
means or percentages as appropriate. Crude (unadjusted) 
comparisons between FACILITIES (A vs. B), BONE 
TYPE (VB vs. IL), and BODY COOLING (Yes or No) 
were tested using independent-groups t-Tests or z-tests 
for proportions.
Statistical modeling
Details of our general modeling approach are provided 
in the Additional file: Appendix S2. Briefly, the asso-
ciations of ischemia times with outcomes were initially 
investigated in unadjusted regression models using only 
ischemia times as predictors. Additional models were 
then estimated to determine the separate associations 
of EXPERIENCE with outcomes. Finally, the effects 
of ischemia were evaluated in multivariable models, 
which controlled for the potential influences of FACIL-
ITY, EXPERIENCE, BONE TYPE, DONOR SEX, and 
DONOR AGE. Separate models were estimated for 
each of the three outcomes of interest (%CD34 + , CFU-
TOTAL, and CFU-GM).
Ordinary least-squares (OLS) linear regression was 
initially employed to test a range of candidate models, 
including models incorporating two-way interactions, 
as well as logarithmic and second-order polynomial 
terms. From these candidates, the best reduced models 
were selected. Criteria used to select reduced models are 
described in Additional file: Appendix S2.
Because %CD34+ is a proportion, limited to the unit 
interval, [0 ≤ (%CD34+) ≤ 1], we found that traditional 
OLS linear regression produced unrealistic fitted values 
exceeding these interval boundaries. To correct for this, 
we substituted beta regression [21] for linear regression 
in models of %CD34+. Beta regression is useful in situa-
tions where the response variable is a rate or proportion 
measured on a continuous scale and bounded by mini-
mum and maximum values. A technical description of 
beta regression is provided in Additional file: Appendix 
S2.
Model validation
Final models were validated using leave-one-out boot-
strap cross-validation [22], which was accomplished by 
randomly omitting one observation with replacement 
from the dataset and re-estimating the model from the 
remaining observations. The resulting model was then 
used to predict the omitted observation. This procedure 
was repeated 200 times, yielding 200 models with pre-
dicted values, model coefficients, standard errors, and 
95% confidence intervals. Model parameters were sum-
marized as averages of the 200 bootstrapped models. 
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Since bootstrap models are naïve to the omitted observa-
tions, this form of validation serves as an estimate of the 
predictive accuracy likely to be seen when the original 
model is used to predict new observations [23]. Model 
coefficients are reported for the original models and 
compared with averaged coefficients ± 95% confidence 
intervals from the 200 cross-validated models.
Results
Sample characteristics are provided in Table 2.
The statistical distributions of individual ischemia-time 
components WIT, CIT, and body cooling time (BCT) 
ordered by total ischemia time, for each of 62 donors is 
provided in the Additional file: Appendix S3, Figure S1.
Unadjusted comparisons
Comparisons of FACILITY, BONE TYPE, and BODY 
COOLING are displayed in Additional file: Appendix 
S4,  Table  S4. The distributions of donor age and donor 
sex did not differ significantly by FACILITY, BONE 
TYPE, or whether BODY COOLING was used.
Processing facilities differed significantly in the distri-
bution of BONE TYPE (27% of the bones processed at 
Facility A were VBs, while 100% of the bones processed 
at Facility B were VBs), which occurred because Facility 
B was structured to receive VBs only. Facility A also had 
more processing experience (Facility A = 53 bones pro-
cessed vs. Facility B = 24 bones processed; p < 0.00001), 
longer WITs (Facility A = 3.55  h vs. Facility B = 2.13  h; 
p = 0.003), and shorter CITs (Facility A = 19.55  h vs. 
Facility B = 28.38  h; p = 0.004). The two facilities did 
not differ significantly in either BCT or total-ischemia 
time. Outcomes between the two facilities differed only 
for CFU-GM counts, with Facility A having significantly 
lower counts than Facility B (28.38 vs. 64.31, respectively; 
p = 0.04). No differences were detected in the percent-
age of viable CD34+ or CFU-TOTAL. Facility differences 
were controlled in final regression models.
Differences in BCT by BONE TYPE (middle section of 
Additional file: Appendix S4,  Table  S4) approached sig-
nificance (p = 0.09), with the processing of VBs associ-
ated with shorter BCTs (6.32 h) compared to IL (8.51 h). 
This occurred because Facility B, which processed only 
VBs, had shorter BCTs than Facility A. Outcomes also 
differed by BONE TYPE. Compared to IL, VBs yielded 
higher numbers of CFU-TOTAL (341.29 vs. 97.44 per 
 105 cells, respectively; p = 0.02) and CFU-GM (50.46 vs. 
18.03 per  105 cells, respectively; p = 0.04). BONE TYPE 
was controlled in final regression models.
In cases where the body was refrigerated prior to bone 
recovery (right most section of Additional file: Appen-
dix S4, Table S4), mean WITs tended to be significantly 
shorter (2.65  h with, vs. 3.98  h without body cooling, 
p = 0.04). The same was true for CITs (19.51 h with, vs. 
28.83  h without body cooling, p = 0.009). It is notewor-
thy that all outcomes were worse when body cooling was 
employed. Mean %CD34+ viability was 72.75% with, 
vs. 89.86% without body cooling (p = 0.0001). Similarly, 
with and without body cooling the average CFU-TOTAL 
count was 100.16 vs. 659.00 per  105 TNC plated, respec-
tively (p ≤ 0.00001), and the average CFU-GM count 
was 18.52 vs. 94.85 per  105 TNC plated, respectively 
(p < 0.00001). Body cooling was accounted for in both ini-
tial and final ischemia-time regression models.
Ischemia‑time regression models
Unadjusted (base) regression models used only WIT, 
BCT, and CIT as predictors (no adjustments for other 
covariates). These models are summarized in the Addi-
tional file: Appendix S3, Tables S3  (a–c). Since BONE 
TYPE, FACILITY, and EXPERIENCE were found to be 
significant variables associated with outcomes (Addi-
tional file: Appendix S4, Table S4), adjusted models were 
developed to control statistically for the influence of 
these other covariates.
The  adjusted beta regression model predicting 
%CD34+ viability is shown in Additional file: Appen-
dix S4, Table S5. (Details of beta regression are provided 
in the Additional file: Appendix S2). The percentage of 
viable CD34+ cells that were recovered, declined signifi-
cantly as a function of increasing BCT, with the decline 
occurring at a diminishing rate as %CD34+ approached 
zero (linear effect, p = 0.002; second-order polynomial 
effect, p = 0.03). A similar curvilinear decline in %CD34+ 
occurred in relation to increasing CIT (linear effect, 
Table 2 Sample characteristics. Numbers are those 
associated with the %CD34+ model
a Average number of cases processed prior to the current case
Mean/percent ± Std error Min Max
Bone type (% vertebrae) 65.2% 5.32% – –
Donor sex (% male) 77.2% 0.54% – –
Donor age (years) 41.2 1.6 13 64
Experiencea 26.9 1.2 0 53
Warm ischemia (h) 3.6 0.4 0.05 13.4
Body cooling (h) 7.9 0.9 0 22.5
Cold ischemia (h) 19.6 1.2 7.4 67.8
Total ischemia (h) 31.0 1.2 15.3 70.5
Outcomes
 %CD34+ viability 
(n = 75)
79.3% 3.0% 15.1% 100%
 CFU-TOTAL/105 cells 
(n = 67)
250.3 49.5 0 1850
 CFU-GM/105 cells 
(n = 66)
38.2 7.8 0 282
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p = 0.003; second-order polynomial effect, p = 0.005). 
Neither BONE TYPE nor WIT were significant. EXPE-
RIENCE (p = 0.09) and the FACILITY x EXPERIENCE 
interaction (p = 0.07) approached statistical significance. 
Odds ratios measure the change in %CD34+ associ-
ated with a one-unit change in the associated predictor 
variable. For example, the odds ratio associated with a 
1-h increase in WIT is 0.9663, indicating that each one-
hour increase in WIT reduces %CD34+ to 96.63% of 
its previous value. The model’s predictive validity is evi-
denced by the similarity of the estimated parameters of 
the original model (left panel of Additional file: Appen-
dix S4, Table S5) to the average of those of the bootstrap 
models (right panel). The model is statistically significant 
(p = 0.001).
Results of the  adjusted linear regression of CFU-
TOTAL is shown in Additional file: Appendix 
S4,  Table  S6. Here the importance of BONE TYPE 
as a source of BM cells is revealed. When BM cells 
were recovered from VB rather than IL, CFU-TOTAL 
increased by 207/105 TNC plated (p = 0.025). The effect 
of BCT on CFU-TOTAL was negative. As BCT increased, 
the recovery of CFU-TOTAL decreased, with the decline 
occurring at a diminishing rate (linear effect, p = 0.00005; 
second-order polynomial effect, p = 0.002). The effects of 
WIT and CIT were not statistically significant. EXPERI-
ENCE also was not significant; however, EXPERIENCE 
was retained because model performance improved 
when EXPERIENCE was controlled statistically. When 
BONE TYPE and EXPERIENCE were both controlled 
statistically, the model’s explanatory power improved 
from  R2 = 35% to 47%. The adjusted  R2 also improved 
from 35% to 40%, indicating that the improvement was 
not the result of model over-specification. Model pre-
cision also improved, as indicated by smaller standard 
errors. The similarity of the estimated parameters of 
the original model (left panel of Additional file: Appen-
dix S4, Table S6) to the averaged results of the bootstrap 
models (right panel) is evidence of the model’s predictive 
validity. The model was significant (p = 0.000005) and 
explained 47.3% of the total variation in CFU-TOTAL.
Results of the adjusted  linear regression of CFU-GM 
are shown in Additional file: Appendix S4,  Table  S7. 
The best CFU-GM model included BONE TYPE as 
a control variable, but not EXPERIENCE or FACIL-
ITY. Although BONE TYPE was not statistically signifi-
cant, it was retained in the model because its inclusion 
improved the explanatory power from  R2 = 32% to 34%, 
while the adjusted  R2 remained the same (29%), sug-
gesting the model was not over-specified. With BONE 
TYPE controlled statistically, WIT and BCT continue 
to demonstrate statistically significant associations with 
CFU-GM. Each passing hour of WIT reduces CFU-GM 
by − 7.19/105 TNC plated (p = 0.03), while each hour 
of BCT reduces CFU-GM by − 5.24/105 TNC plated 
(p = 0.00003). CIT had no effect (p = 0.86). The model’s 
predictive validity is evidenced by the similarity in the 
parameters of the original model (left panel of Additional 
file: Appendix S4, Table S7) to the averaged results of the 
bootstrap models (right panel). The model is significant 
(p < 0.00001) and explains one-third of the variability in 
CFU-GM.
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1 90% 89% 88% 88% 87% 86% 86% 85% 84% 84% 83% 82% 82% 81% 81% 80% 80% 80% 79% 79% 79% 78% 78% 78% 78% 78% 78%
2 89% 89% 88% 87% 86% 86% 85% 84% 84% 83% 82% 82% 81% 81% 80% 80% 79% 79% 79% 78% 78% 78% 78% 78% 78% 78% 78%
3 89% 88% 87% 87% 86% 85% 85% 84% 83% 83% 82% 81% 81% 80% 80% 79% 79% 78% 78% 78% 78% 77% 77% 77% 77% 77% 77%
4 89% 88% 87% 86% 86% 85% 84% 83% 83% 82% 81% 81% 80% 80% 79% 79% 78% 78% 77% 77% 77% 77% 77% 76% 76% 76% 76%
5 88% 87% 87% 86% 85% 84% 84% 83% 82% 82% 81% 80% 80% 79% 79% 78% 78% 77% 77% 77% 76% 76% 76% 76% 76% 76% 76%
6 88% 87% 86% 86% 85% 84% 83% 83% 82% 81% 80% 80% 79% 79% 78% 78% 77% 77% 76% 76% 76% 75% 75% 75% 75% 75% 75%
7 87% 87% 86% 85% 84% 84% 83% 82% 81% 81% 80% 79% 79% 78% 77% 77% 76% 76% 76% 75% 75% 75% 75% 75% 74% 74% 74%
8 87% 86% 85% 85% 84% 83% 82% 82% 81% 80% 79% 79% 78% 77% 77% 76% 76% 75% 75% 75% 74% 74% 74% 74% 74% 74% 74%
9 87% 86% 85% 84% 83% 83% 82% 81% 80% 79% 79% 78% 77% 77% 76% 76% 75% 75% 74% 74% 74% 73% 73% 73% 73% 73% 73%
10 86% 85% 85% 84% 83% 82% 81% 80% 80% 79% 78% 77% 77% 76% 76% 75% 75% 74% 74% 73% 73% 73% 73% 73% 72% 72% 72%
Fig. 2 Predicted values from the %CD34+ beta regression model generated from the coefficients in Additional file: Appendix 4, Table S5. 
Calculated values in each square represent the percentage of viable CD34+ cells recovered from whole BM. The gradient of shading demonstrates 
the overall interrelationship between WIT and CIT. Green shading represents values above 80% viability, red shading below 80% and yellow near 
an 80% threshold. Input values used in the beta regression model to calculate CD34+ viability predictions were as follows: BCT = 0 h (no body 
cooling); Facility B = 0 (Indianapolis); Experience = 12 (mean for Indianapolis); Bone Type VB = 1 (vertebral bodies). WIT and CIT values are varied 
from the 10th to 90th percentile of observed values
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Predictions of cell viability from %CD34+ model
The pattern of predictions shown in Fig. 2 illustrates how 
various combinations of WIT and CIT alter the viability 
of recovered CD34+ cells. These predictions were gener-
ated from the beta regression model of Additional file: 
Appendix S4, Table S5 with BCT set to zero (i.e., no body 
cooling). Green shading represents predicted CD34+ 
viabilities above 80%, red shading below 80%, and yel-
low near an 80% threshold. Figure 2 shows, as one would 
expect, that WIT is more detrimental to cell viability 
than CIT. When WIT is held to 3 h or less, the viability of 
CD34+ cells remains at or above 80% (green region) for 
up to 24 h of CIT. However, as WIT is extended beyond 
3 h, the amount of CIT that can be tolerated is progres-
sively shortened. We did not test the effect of cryopreser-
vation; therefore, these predictions do not account for 
possible loss of viability due to subsequent freezing and 
thawing of recovered cells. The lesson from Fig. 2 is that 
longer total ischemia times can be tolerated when warm 
ischemia is kept to a minimum. Similar predictions for 
CFU-TOTAL and CFU-GM can be made using the coef-
ficients provided in Additional file: Appendix S4, Tables 
S6 and S7.
Discussion
In terms of total numbers of donors and number of bones 
procured, this pragmatic observational study is the larg-
est to date, and the first to quantify the influences of 
ischemia and body-cooling times on the quality of HSPCs 
recovered from the bones of deceased donors under real-
istic field conditions. Because the study was designed to 
optimize externally valid inferences, i.e., inferences that 
are generalizable to usual practice settings, the study cov-
ers the full continuum of ischemia times likely to be seen 
under normal OPO operating conditions, and differs 
from previous studies conducted at single institutions, 
where donor bones were recovered immediately after 
cardiac arrest (i.e., no body cooling), with rapid bone 
recovery (i.e., short WIT), and without the need for long 
periods of transport (i.e., reduced CIT) [4, 14, 15].
The study results convey four principal messages. First, 
acceptable levels of HSPC quality are achievable despite 
the prolonged ischemia times that are inevitable when 
bones must be procured by geographically dispersed 
OPOs and shipped cross-country to a distant processing 
center. Our analyses show that under such conditions, 
favorable combinations of warm- and cold-ischemia 
times are achievable, enabling CD34+ cell viabilities in 
the range of 80–90%. Overall, the mean percentage of 
viable CD34+ cells recovered over all ischemia times was 
just under 80% (79.3%, Table 2).
The second message is that refrigerating the body 
prior to bone recovery, a practice that is common in the 
recovery of tissues, is detrimental to the viability and 
function of HSPCs recovered from deceased donor BM. 
Previous studies have demonstrated it takes over 10 h for 
a 37 °C, 70 kg body to cool to 4 °C when placed into a 4 °C 
morgue refrigerator [24]. This process is dependent upon 
body weight and is dynamic. The cooling curve becomes 
asymptotic as the body approaches the surrounding tem-
perature and is much slower than cooling a smaller mass 
such as a block of VBs weighing ~ 3 kg on wet ice. While 
body cooling has been demonstrated to be appropri-
ate for the recovery of non-viable tissues, in the context 
of bone marrow recovery either the duration of time at 
metabolically relevant temperatures, the longer cooling 
curve, or an interaction of both is apparently detrimental. 
When whole-body cooling was used, CD34+ cell viability 
averaged 72.75%; when body cooling was not used, aver-
age viability increased to nearly 90% (89.96%, Additional 
file: Appendix S4, Table S4), suggesting that the optimal 
practice would be to dispense with body cooling and 
transfer recovered bone as quickly as possible to a cold 
ischemic environment.
Third, our analyses suggest that the source of BM (bone 
type) matters. In unadjusted comparisons, CD34+ cell 
viabilities were > 80% when VBs were the source, vs. 
< 74% when IL were the source. Similarly, CFU-TOTAL 
and CFU-GM counts for VBs vs. IL were 341.29 vs. 97.44, 
and 50.46 vs. 18.03, respectively (Additional file: Appen-
dix S4, Table S4). The reason for these differences is not 
entirely clear and is probably multifaceted. It is likely 
that variation in the recovery and isolation process used 
with the two bone types played a more important role 
than physiological differences. For example, VBs were 
exposed to fewer hours of body cooling on average than 
IL (6.32 vs. 8.51 h, respectively; Additional file: Appendix 
S4, Table S4), and body cooling, in turn, was associated 
with poorer outcomes. When the influence of body cool-
ing was controlled in regression models, the differences 
in outcomes between VB and IL were reduced for CFU-
TOTAL (Additional file: Appendix S4,  Table  S6), and 
were reduced and became statistically nonsignificant for 
CFU-GM (Additional file: Appendix S4, Table S7). Thus, 
the observation that VBs yield higher-quality HSPCs 
than IL is partially explained by the skewed distribution 
of body cooling between the two bone types. The influ-
ence of VB on %CD34+ was not statistically significant 
in unadjusted comparisons (Additional file: Appendix 
S4, Table S4), and remained nonsignificant after adjusting 
for body cooling (Additional file: Appendix S4, Table S5). 
Given that this is the first study to compare BM from 
deceased donor VBs and IL, no other directly compara-
ble data exist. The closest approximation is comparisons 
of the viability of CD34+ cells recovered from the BM 
Page 9 of 11Woods et al. J Transl Med          (2020) 18:300  
of deceased donor VBs and living donor aspirated iliac 
crest, which showed no difference [25–27].
The fourth message that our analysis conveys is that 
experience (learning) is a relevant factor that may vary 
substantially across different processing centers. As with 
most technical activities, the processing of BM cells from 
deceased donor bone follows a learning curve. It is well 
established that the products of industrial manufacturing 
improve with learning, a phenomenon first documented 
over 80 years ago [28] and subsequently incorporated into 
standard textbooks on operations management [17, 29]. 
In more recent times, it has been shown that the learn-
ing-curve phenomenon extends to both the outcomes 
and costs of medical procedures [18–20]. We observed 
different learning trajectories in the BM processing cent-
ers we studied, and, although we analyzed only two cent-
ers, our results suggest that the pace of learning and the 
shape of the learning curve may vary substantially across 
centers, a factor that should be considered in the design 
of future training programs, BM processing protocols, 
and certification practices. Our analysis implies that a 
volume-outcome relationship exists for the processing 
of BM and that a high-volume, regional center that has 
accumulated more processing experience may produce 
a higher-quality BM product compared to a low-volume 
center.
The intent of the present study was not to optimize 
yield or viability; however, some comparisons can be 
made to previous reports of deceased human-donor BM 
recovery, where optimization was the goal. Three previ-
ous studies have compared BM from a combined total 
of 99 deceased donors to that of a combined 58 living 
donors [25–27]. In these reports, the percentage of via-
ble CD34+ cells from deceased donor BM (2.1 ± 0.6%; 
mean ± standard deviation) was not statistically dif-
ferent (p = 0.32) than BM aspirated from living donors 
(1.56 ± 0.92%). This compares well with our findings, in 
which the average percentage of CD34+ cells recovered 
was 2.43 ± 0.64% (mean ± SEM). We did observe greater 
variation in CD34+ percentages, which likely reflects the 
extreme range of ischemia times and, consequently, the 
quality of donor tissue on arrival in our study. Addition-
ally, in this study the average total nucleated cell counts 
recovered from each donor was 9.1 × 107 (range: 1.3 × 106 
to 6.4 × 108) per gram of bone processed from an average 
bone weight of 312.4 ± 58  g (mean ± SEM). This would 
equate to CD34+ cell yields ranging from ~ 32,000 to 
> 155 M per donor. Again, this range reflects an extreme 
span of ischemia times as this study was intended to 
determine acceptable boundaries to carry forward into 
subsequent research. Previous studies under ideal con-
ditions have reported TNC recoveries of 5.1 ± 1.1 × 1010 
(mean ± SD) [4, 14, 15].
The quality of deceased-donor CD34+ HSPCs also 
has been compared to living-donor HSPCs by assay-
ing CD34+ cell viability and CFU potential [25–27]. 
These studies reported a mean viability of 95.2 ± 3.6% 
for CD34+ cells recovered from deceased donors, com-
pared to 93.5 ± 0.35% for living donors. Functional equiv-
alency of deceased-donor and living-donor BM HSPCs, 
established by comparing the frequency of CFU-GM, 
was 105 ± 65 per  105 TNC plated in deceased-donor 
BM, compared to 81.4 ± 17 per  105 TNC plated in liv-
ing donor BM. By comparison, our overall averages from 
deceased-donor BM (Table 2 and Additional file: Appen-
dix S4, Table  S4) were lower for both of these quality 
metrics, presumably due, again, to the extreme range of 
ischemia times and the inclusion of body cooling in our 
study, which negatively impacted average cell function-
ality. We have subsequently used the findings reported 
here to establish limits of 8  h WIT and 40  h CIT, and 
have eliminated the practice of body cooling. Following 
this protocol change, vertebrae from 50 donors meet-
ing these restrictions have now been recovered and pro-
cessed (manuscript in preparation). The average CD34+ 
HSPC viability was 90.5 ± 1.9% and the average CFU-GM 
was 158.3 ± 13.5/105 TNC plated, which is comparable to 
the previous studies [25–27].
Overall, our study demonstrates the feasibility of 
recovering viable BM from deceased donors for bank-
ing. Building a BM bank with sufficient HLA diversity 
requires an ample source and steady supply of deceased-
donor medullary bones. Fortunately, the Uniform Ana-
tomical Gift Act of 1968 established a syndicate of 58 
geographically distributed OPOs. Each year approxi-
mately 10,000 deceased individuals donate their organs, 
and a further 40,000 donate tissues, yielding approxi-
mately 30,000 organs and over a million tissues recov-
ered annually (unos.org/data/transplant-trends/accessed 
16 March 2020). The high volume of bones potentially 
recoverable through this network, could provide the 
necessary inventory to justify the establishment of an 
integrated system of bone procurement, recovery, and 
transport, linked to BM processing and banking cent-
ers. An integrated system of this type would require the 
cooperation and coordination of multiple OPOs all fol-
lowing agreed-upon operational protocols. Our study 
demonstrates the feasibility of building such a system 
using existing OPO infrastructure. In particular, we have 
demonstrated that protocols designed to maintain a 
favorable ischemic environment from the point of bone 
procurement and recovery, through cross-country ship-
ping, to arrival at the BM processing center, can be devel-
oped and enforced. Because our data encompassed the 
full range of body-cooling and ischemia times likely to 
be seen in practice, they possess a high level of external 
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validity (generalizability), and our predictive models 
(Fig.  2) can be used to establish realistic ischemia-time 
tolerance limits for satisfying HSPC quality-acceptance 
standards.
The creation of a BM banking system would offer 
several distinct advantages over current living-donor 
registries. First, personal risk to live donors would be 
obviated, as opposed to only ameliorated through the 
present predominant practice of mobilized peripheral 
blood collection. Second, much larger volumes of HSPCs 
can be recovered from a deceased donor compared to 
a living donor, allowing for multiple or repeat infusions 
from the same donor in cases of graft failure. Addition-
ally, recovered cells can be packaged in known quantities, 
tested for quality, and cryopreserved for later on-demand 
use. Because the units are cryopreserved, they can be 
stored indefinitely [30], thereby obviating the problem of 
attrition that occurs with living-donor registries. Finally, 
a BM bank can serve as a readily available resource dur-
ing surges in demand following a mass casualty event, 
such as a nuclear disaster resulting in widespread bone-
marrow failure [1, 2].
Conclusions
Deceased-donor BM banking is now coming into exist-
ence and is beginning to display significant potential. 
From the perspective of a nascent processing facility, the 
results of our statistical models can be used to establish 
quantitative ischemia tolerance limits and quality accept-
ance standards for safeguarding the viability and function 
of HSPCs derived from deceased-donor bone. From a 
broader policy perspective, our models can also provide 
the foundation for an emerging BM banking system to 
institute data-driven industry standards.
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